IL-28, IL-29 and their class II cytokine receptor IL-28R

By P. Sheppard, W. Kindsvogel, Wenfeng Xu, K. Henderson, S. Schlutsmeyer, T. Whitmore, R. Kuestner, U. Garrigues, C. Birks, Jenny Roraback and 16 more. Nature Immunology, 2002

1,671 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/c54550338e6d46cf081529efee04067e2e64438f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Interferon signalling network in innate defence (2006, background): “Newly identified IFN members, IFN-λs or IL-28/29, have been identified by two different research groups (Kotenko et al., 2003; Sheppard et al., 2003; Vilcek, 2003) (Table 1).”
Zika virus targets human STAT2 to inhibit type I interferon signaling (2016, background): “Type III IFN utilizes different cell-surface receptors than type I IFN, but utilizes the same JAK-STAT machinery, including STAT2 (Kotenko et al., 2003; Sheppard et al., 2003).”
Interferon-Stimulated Genes: A Complex Web of Host Defenses (2014, background): “The type III IFNs—IFNL1, IFNL2, and IFNL3 [also known as IFN-λ1, IFN-λ2, and IFN-λ3, or interleukin (IL)-29, IL-28A, and IL-28B, respectively]—were described independently by two research groups in 2003, making them the most recently discovered members of the IFN family (34, 35).”
A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures (2020, background): “week-old BALB/c mice against SARS-CoV-2 spike (S), nucleocapsid (N), and GFP as a control, Interferon lambda is a type III interferon whose receptors are largely limited to epithelial cells, including the lungs, liver, and gastrointestinal tract 16, 17 lowered nasal turbinate titer compared to vehic”
Into the Eye of the Cytokine Storm (2012, background): “Lambda IFNs are a new class of IFN with antiviral properties (127), protecting mice against influenza A virus (106).”
IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo (2008, background): “Type III IFN (also called IFN-l or IL-28/29) is structurally and genetically close to the members of the IL-10 family of cytokines but displays type I IFN-like activity [14,15].”
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C (2009, background): “The three cytokines are induced by viral infection and have antiviral activit”
Interferons, interferon‐like cytokines, and their receptors (2004, background): “IFN-gR1 IFN-gR (220), IFN-gRa (221) 6q23þ2 (C) IFN-g IFN-gR2 AF-1 (90), IFN-gRb (91) 21q22þ11 (T) IFN-g IFN-aR1 IFN-aR (66) 21q22þ11 (T) IFN-a, IFN-b, IFN-o, IFN-d, IFN-e, IFN-k, IFN-l, limitin IFN-aR2 IFN-a/bR (222), IFN-aR2a (65), IFN-aR2b, 21q22þ11 (T) IFN-a, IFN-b, IFN-aR2c, IFN-aR2L (69), IFN-o”
IFN Regulatory Factor Family Members Differentially Regulate the Expression of Type III IFN (IFN-λ) Genes1 (2007, background): “Quite recently a new class of antiviral cytokines, type III IFNs (IFN- 1–3 or IL-28/29), which are genetically and structurally different from type I IFNs, were identified (1, 2).”
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (2009, background): “Because they regulate similar genes as IFN-α but are more specific in their tissue targets, these interleukins have been suggested as an alternative therapy to IFN-α with possibly fewer adverse effect”